Clinical Trial

BNHL-2015 for Children or Adolescents in China

Study acronym: BNHL-2015
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test whether adding 4 injections of rituximab and increasing the intensity of chemotherapy regimens in advanced patients can improve the EFS compared with the historical study CCCG-NHL-2010.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2015-03-28; most recent amendment 2026-03-17.
Status change: Recruiting → Active, Not Recruiting 2021-07-28
Trial Details
NCT Number NCT02405676
Lead Sponsor Children's Cancer Group, China
Collaborators: Tongji Hospital, Nanjing Children's Hospital, West China Second University Hospital, Xiangya Hospital of Central South University, Qilu Hospital of Shandong University, Children's Hospital of Soochow University, Tianjin Medical University Cancer Institute and Hospital
Conditions Mature B-cell Non-Hodgkin Lymphoma
Enrollment 200 participants
Start Date 2015-01-01
Primary Completion 2023-12-31 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-19